NLTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NLTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
Neoleukin Therapeutics's adjusted free cash flow per share for the three months ended in Sep. 2023 was $-1.538. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-31.55 for the trailing ten years ended in Sep. 2023.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.
As of today (2024-10-31), Neoleukin Therapeutics's current stock price is $3.49. Neoleukin Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2023 was $-31.55. Neoleukin Therapeutics's Cyclically Adjusted Price-to-FCF of today is .
The historical data trend for Neoleukin Therapeutics's Cyclically Adjusted FCF per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neoleukin Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Cyclically Adjusted FCF per Share | Get a 7-Day Free Trial | - | - | - | - | -31.43 |
Neoleukin Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Cyclically Adjusted FCF per Share | Get a 7-Day Free Trial | -31.83 | -31.43 | -32.05 | -31.90 | -31.55 |
For the Biotechnology subindustry, Neoleukin Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Neoleukin Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Neoleukin Therapeutics's Cyclically Adjusted Price-to-FCF falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?
Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.
We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Neoleukin Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2023 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Sep. 2023 (Change) | * | Current CPI (Sep. 2023) |
= | -1.538 | / | 129.8595 | * | 129.8595 | |
= | -1.538 |
Current CPI (Sep. 2023) = 129.8595.
Neoleukin Therapeutics Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201312 | -7.458 | 98.326 | -9.850 |
201403 | -24.248 | 99.695 | -31.585 |
201406 | -5.378 | 100.560 | -6.945 |
201409 | -7.850 | 100.428 | -10.151 |
201412 | -12.541 | 99.070 | -16.439 |
201503 | -11.765 | 99.621 | -15.336 |
201506 | -10.073 | 100.684 | -12.992 |
201509 | -7.806 | 100.392 | -10.097 |
201512 | -4.598 | 99.792 | -5.983 |
201603 | -6.851 | 100.470 | -8.855 |
201606 | -9.534 | 101.688 | -12.175 |
201609 | -8.742 | 101.861 | -11.145 |
201612 | -7.753 | 101.863 | -9.884 |
201703 | -9.725 | 102.862 | -12.277 |
201706 | -9.084 | 103.349 | -11.414 |
201709 | -9.852 | 104.136 | -12.286 |
201712 | -9.907 | 104.011 | -12.369 |
201803 | -13.313 | 105.290 | -16.420 |
201806 | 7.678 | 106.317 | 9.378 |
201809 | -13.062 | 106.507 | -15.926 |
201812 | -8.305 | 105.998 | -10.175 |
201903 | -2.342 | 107.251 | -2.836 |
201906 | -1.249 | 108.070 | -1.501 |
201909 | -4.990 | 108.329 | -5.982 |
201912 | -2.661 | 108.420 | -3.187 |
202003 | -2.664 | 108.902 | -3.177 |
202006 | -3.954 | 108.767 | -4.721 |
202009 | -0.221 | 109.815 | -0.261 |
202012 | -3.618 | 109.897 | -4.275 |
202103 | -5.259 | 111.754 | -6.111 |
202106 | -5.259 | 114.631 | -5.958 |
202109 | -3.393 | 115.734 | -3.807 |
202112 | -4.560 | 117.630 | -5.034 |
202203 | -5.275 | 121.301 | -5.647 |
202206 | -4.176 | 125.017 | -4.338 |
202209 | -3.478 | 125.227 | -3.607 |
202212 | -3.993 | 125.222 | -4.141 |
202303 | -4.855 | 127.348 | -4.951 |
202306 | -1.489 | 128.729 | -1.502 |
202309 | -1.538 | 129.860 | -1.538 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Neoleukin Therapeutics (NAS:NLTX) Cyclically Adjusted FCF per Share Explanation
If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.
For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Be Aware
Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.
Thank you for viewing the detailed overview of Neoleukin Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Baker Bros. Advisors Lp | 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Sean Michael Smith | officer: Principal Accounting Officer | C/O NEOLEUKIN THERAPEUTICS, INC., 188 E. BLAINE STREET, SUITE 450, SEATTLE WA 98102 |
Priti Patel | officer: Chief Medical Officer | C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE WA 98102 |
Erin Lavelle | director | C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011 |
Donna Cochener | officer: General Counsel, SVP Legal | C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, SUITE 450, SEATTLE WA 98102 |
Rohan Palekar | director | 201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105 |
Jonathan G Drachman | director, officer: See Remarks | 21823 30TH DRIVE SE, BOTHELL WA 98021 |
Carl Walkey | officer: Senior Vice President | C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102 |
Robert Ho | officer: Chief Financial Officer | 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102 |
Holly Vance | officer: General Counsel | C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE E., SEATTLE WA 98102 |
Martin Babler | director | C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Erin M. Lavelle | director | 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102 |
Redmile Group, Llc | 10 percent owner | ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
Jeremy Green | 10 percent owner | 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001 |
Sarah B. Noonberg | director | 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By Marketwired • 08-17-2023
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By PRNewswire • 07-24-2023
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.